

Conclusion: We present the first expert panel consensus on recommendations for standardised baseline patient data collection in obesity management services in Australia. Standardising data collections will minimise variation in clinical assessment and facilitate data pooling for clinical audit, health service planning, as well as future research activities.

References

- [1] Atlantis E, Kormas N, Samaras K, Fahey P, Sumithran P, Glastras S, et al. Clinical Obesity Services in Public Hospitals in Australia: a position statement based on expert consensus: Expert consensus on clinical obesity services. *Clinical Obesity* 2018;8(3):203–10.
- [2] Jünger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: Recommendations based on a methodological systematic review. London, England: SAGE Publications; 2017. p. 684–706.

<https://doi.org/10.1016/j.orcp.2018.11.089>

85

Low copy number of the salivary amylase gene (AMY1) are associated with obesity, dyslipidemia and chronic low-grade inflammation but not insulin sensitivity and secretion



Barbora De Courten*, Aya Mousa, Negar Naderpoor, Regina Belski

Low salivary amylase gene (AMY1) copy number variations (CNVs) are associated with low serum amylase concentrations which have been shown to correlate with obesity, metabolic syndrome and predict type 2 diabetes. Recently, AMY1 CNV below 4 has been associated higher risk of obesity. Only one study has shown an association between AMY1 CNV and insulin resistance (HOMA).

We assessed the relationship between AMY1 CNVs and adiposity (body mass index and dual X-ray absorptiometry), fasting and 2 hour glucose (75 g OGTT), insulin sensitivity (hyperinsulinemic euglycemic clamp) and total, first and second phase insulin secretion (intravenous glucose tolerance test), inflammatory markers and adipokines (multiplex assays, Biologend, CA) in 58 overweight and obese but otherwise healthy individuals (age 31 ± 9 years, BMI 31 ± 4 kg/m²). Participants were non-smokers and had modest alcohol consumption. The participants were divided into two groups according to a median of 4 AMY1 CNVs.

Individuals with less than 4 AMY1 CNVs had higher BMI (33 ± 4 vs 30 ± 3 kg/m², $p=0.04$), fat mass (41 ± 12 vs 34 ± 8 kg, $p=0.01$), LDL cholesterol (3.3 ± 0.8 vs 2.8 ± 0.7 mmol/l, $p=0.02$), plasma interleukin 6 (53 ± 56 vs 24 ± 22 pg/ml, $p=0.02$) and leptin concentrations (0.83 ± 0.56 vs 0.50 ± 0.46 ng/ml, $p=0.02$) compared to individuals with more than 4 AMY1 CNVs. There was no relationship between AMY1 CNVs and insulin sensitivity, insulin secretion, plasma fasting and 2 hour glucose, high sensitivity C-reactive protein, adiponectin, resistin and adipon levels (all $p > 0.1$).

Our data indicated that AMY1 CNVs are associated with obesity, dyslipidemia and chronic low-grade inflammation but not glucose metabolism. Further larger studies are needed to confirm whether AMY1 CNVs could be a genetic biomarker for metabolic syndrome and type 2 diabetes.

<https://doi.org/10.1016/j.orcp.2018.11.090>

86

Hypothalamic hunger promoting neurons drive life



Tamas Horvath

Yale University, New Haven, CT, United States

Abstract not available.

<https://doi.org/10.1016/j.orcp.2018.11.091>

87

Novel circulating biomarkers identify insulin resistance phenotypes in obesity



Yen Chin Koay^{1,2,â^}, Pengyi Yang³, Daniel Chen⁴, Arthur B. Jenkins^{4,5}, Jerry Greenfield^{4,6,7}, John F. O'Sullivan^{1,2,8,9}, Dorit Samocha-Bonet^{4,5,9}

¹ Heart Research Institute, Camperdown, New South Wales, Australia

² Sydney Medical School, University of Sydney, Camperdown, New South Wales, Australia

³ School of Mathematics and Statistics, University of Sydney, Sydney, New South Wales, Australia

⁴ Diabetes and Metabolism Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia

⁵ School of Medicine, University of Wollongong, Keiraville, New South Wales, Australia

⁶ St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia

⁷ Department of Endocrinology and Diabetes Centre, St Vincent's Hospital, Sydney, New South Wales, Australia

⁸ Royal Prince Alfred Hospital, Department of Cardiology, Sydney, New South Wales, Australia

Objective: Measurement of insulin resistance may ultimately assist in guiding the most effective therapy in type 2 diabetes (T2D). We aimed to identify circulating biomarkers of muscle and liver insulin resistance in obesity to guide treatment in the clinical setting.

Research design and methods: Metabolomics and lipidomics were combined with a specialized machine-learning algorithm to identify plasma biomarkers that characterize muscle and liver insulin resistance in a cohort of 62 individuals with obesity (BMI range $31 \text{â} 48$ kg/m²) phenotyped using the gold-standard 2-step hyperinsulinaemic-euglycaemic clamp with deuterated glucose to evaluate glucose regulation in muscle and liver.

Results: Comprehensive metabolomic and lipidomic profiling by LC/MS revealed that a total of fourteen circulating metabolites and lipids were closely correlated with muscle insulin resistance (Spearman $\rho > 0.2$, $p < 0.05$) while nineteen were associated with hepatic insulin resistance (Spearman $\rho > 0.3$, $p < 0.05$). A hybrid learning model that combines clustering-based prototype selection and random forest-based feature analysis identified two triacylglycerols (TAGs) and a phosphatidylcholine (PC) in plasma as the best classifiers differentiating between the liver and muscle insulin resistance phenotypes, followed by select metabolites, clinical features, and biochemical parameters. The three lipids identified by the hybrid learning model far out-performed standard clinical

⁹ O'Sullivan and Samocha-Bonet contributed equally to this work.

measures, including fasting plasma glucose, 2-h plasma glucose post 75 g oral glucose load, glycosylated haemoglobin (HbA1c), and homeostatic model assessment of insulin resistance (HOMA-IR), classifying 61 of 62 subjects correctly.

Conclusions: We provide a simple novel tool based on circulating lipids and metabolites to guide physicians to the most effective insulin-sensitising treatment in individuals with obesity. Future studies are necessary to validate these findings and to compare the efficacy of the biomarker-guided therapy with the traditional treatment.

<https://doi.org/10.1016/j.orcp.2018.11.092>

88

Vitamin D supplementation improves adipokine concentrations in overweight or obese adults



Aya Mousa^{1,*}, Negar Naderpoor¹, Robert Scragg², Barbara De Courten¹

¹ Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, School of Public Health and Preventive Medicine, Melbourne, VIC, Australia

² School of Population Health, The University of Auckland, Auckland, New Zealand

Background: Adipokine dysregulation is a feature of obesity and related cardiometabolic disorders including type 2 diabetes. Vitamin D regulates adipokine production *in vitro*; however, clinical trials have been inconclusive.

Objective: To examine the effects of vitamin D supplementation on serum adipokine concentrations in overweight or obese and vitamin D-deficient adults, using data from a randomized controlled trial (RCT).

Design: Sixty-five individuals with a body mass index (BMI) ≥ 25 kg/m² and 25-hydroxyvitamin D (25(OH)D) ≤ 50 nmol/L were randomized to an oral bolus dose of 100,000 IU followed by 4,000 IU daily of cholecalciferol or matching placebo for 16 weeks. Before and after the intervention, we measured BMI, waist-to-hip ratio (WHR), % body fat (dual energy X-ray absorptiometry), serum concentrations of 25(OH)D (chemiluminescent immunoassay) and total adiponectin, leptin, resistin, and adiponectin (multiplex assay; flow cytometry). Sun exposure habits, physical activity, and diet were assessed using questionnaires.

Results: Fifty-four participants completed the study (35 M/19F; age = 31.9 ± 8.5 years; BMI = 30.9 ± 4.4 kg/m² [mean \pm SD]). After 16 weeks, vitamin D supplementation increased serum 25(OH)D compared with placebo (57.0 ± 21.3 versus 1.9 ± 15.1 nmol/L, $p < 0.001$). There were no differences between vitamin D and placebo groups for changes in adiponectin, leptin, resistin, or adiponectin in unadjusted analyses (all $p > 0.05$). After adjustment for baseline values, season, sun exposure, and dietary vitamin D intake, there was a greater increase in adiponectin (β [95%CI] = 13.7 [2.0, 25.5], $p = 0.02$) and leptin (β [95%CI] = 22.3 [3.8, 40.9], $p = 0.02$) concentrations in the vitamin D group compared with placebo. Results remained significant after additional adjustment for age, sex, and % body fat (both $p < 0.02$).

Conclusions: Vitamin D may increase adiponectin and leptin concentrations in vitamin D-deficient and overweight or obese adults. Further studies are needed to clarify the molecular interactions between vitamin D and adipokines, and to establish the clinical implications of these interactions in the context of obesity.

<https://doi.org/10.1016/j.orcp.2018.11.093>

89

Modification of cognitive biases in overweight and obesity



Naomi Kakoschke^{1,*}, Chloe Hawker¹, Ben Castine¹, Barbara De Courten², Antonio Verdejo-Garcia¹

¹ Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, Victoria, Australia

² Monash Centre for Health Research and Implementation, Monash University, Clayton, Victoria, Australia

Introduction: Obesity is partly driven by unhealthy food choices underpinned by cognitive biases, including approach bias (an automatic tendency to move toward rather than away from appetitive food cues) and delay discounting (a preference for smaller, immediate over larger, delayed rewards). Cognitive training strategies aimed at modifying these biases, namely, approach-avoidance training (AAT) and episodic future thinking (EFT) have been shown to improve food choice. However, previous studies tested these training strategies in single laboratory-based sessions among healthy participants. We conducted a pilot randomised trial to examine the effect of these two trainings, delivered daily for one week via smartphone apps, on approach bias for healthy and unhealthy food, delay discounting, and food choice.

Method: Sixty participants with overweight or obesity (39F; age = 26.93 ± 6.73 years; BMI = 30.34 ± 3.75 kg/m²) were randomly allocated to AAT, EFT, or a waitlist control. Outcomes were measured at pre-training, post-training, and at 6-week follow-up. Additional measurements included weight (kgs) and training engagement.

Results: Training session completion rates were high for AAT (85.71%) and EFT (86.43%), $t(38) = -0.11$, $p = 0.92$. Approach bias for unhealthy food was lower in AAT than EFT at post-training ($M_{\text{Diff}} = -64.56$, $p = 0.02$, 95% CI [-118.83, -10.28]). Healthy food choice (%) was higher for AAT than controls at post-training ($M_{\text{Diff}} = 23.45$, $p = 0.01$, 95% CI [7.26, 39.64], $d = 1.26$), and 6-week follow-up ($M_{\text{Diff}} = 23.92$, $p = 0.01$, 95% CI [5.37, 42.48], $d = 1.24$), and weight reduced from pre-training to 6-week follow-up in AAT ($M_{\text{Diff}} = -0.74$, $p = 0.03$, 95% CI [-1.40, -0.090], $d = 0.47$). However, EFT did not affect delay discounting, food choice, or weight (all p 's > 0.1).

Conclusion: AAT is a useful training strategy for improving food choice in obesity and smartphones are a feasible, engaging way to deliver training.

<https://doi.org/10.1016/j.orcp.2018.11.094>

90

Intermittent compared to continuous energy restriction on weight loss and weight maintenance: effects after 12 months



Michelle Headland*, Peter Clifton, Jennifer Keogh

School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia

Background and aim: There are few long-term trials comparing intermittent energy restriction (IER) to continuous energy restriction (CER) for weight loss. We compared the effects of CER to two forms of IER; a week-on-week-off energy restriction and a 5:2 program on weight loss, body composition, blood lipids and glucose.